Small Molecules

04 Jan 2018 Lycera Announces Initiation of Phase 1b Study of Novel Immuno-Oncology Candidate LYC-55716 in Combination with Pembrolizumab
04 Jan 2018 Avacopan Conditional Marketing Authorization Application Accepted for Regulatory Review by European Medicines Agency
04 Jan 2018 Ultragenyx Announces Update to UX007 Development Program in Long-Chain Fatty Acid Oxidation Disorder Patients
04 Jan 2018 iTeos Therapeutics Regains Worldwide Rights to Clinical-Stage IDO1 Inhibitor
04 Jan 2018 Minoryx Therapeutics announces the dosing of first patient in ADVANCE, a phase 2/3 clinical study of MIN-102 in patients with adrenomyeloneuropathy (AMN)
04 Jan 2018 Inventiva Announces Enrollment of First Patient into Its Odiparcil Phase IIa Trial (iMProveS) for MPS VI
04 Jan 2018 Novartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)
03 Jan 2018 Asana BioSciences Announces Acceptance of IND Application for Its Oral ERK1/2 Inhibitor
03 Jan 2018 Liquidia Initiates Phase 3 Clinical Trial of LIQ861 in Patients with Pulmonary Arterial Hypertension
03 Jan 2018 Trevena Announces FDA Acceptance for Review of New Drug Application for OLINVO™ (oliceridine) Injection
03 Jan 2018 Tetraphase Pharmaceuticals Announces Submission of New Drug Application to FDA for Eravacycline for the Treatment of Complicated Intra-Abdominal Infections (cIAI)
03 Jan 2018 Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer
02 Jan 2018 Syros Announces Clinical Supply Agreement with Janssen to Evaluate SY-1425, Its First-in-Class Selective RARα Agonist, in Combination with Daratumumab in Genomically Defined AML and MDS Patients
02 Jan 2018 Achaogen Announces Positive Top-Line Results from First Clinical Trial of Orally-Administered Antibacterial Candidate C-Scape
02 Jan 2018 Achaogen Announces FDA Acceptance of New Drug Application with Priority Review for Plazomicin for Treatment of Complicated Urinary Tract Infections and Bloodstream Infections
02 Jan 2018 Progenics Pharmaceuticals Completes Enrollment in Phase 3 Study of PSMA-Targeted Imaging Agent 1404
02 Jan 2018 Edge's EG-1962 Phase 3 NEWTON 2 Study Continues as Planned Following Completion of Futility Analysis
29 Dec 2017 Progenics Pharmaceuticals Announces FDA Acceptance of New Drug Application for AZEDRA® (iobenguane I 131) in Pheochromocytoma and Paraganglioma
29 Dec 2017 Ignyta Reports FDA Clearance of IND for RXDX-106, a Novel Immunomodulatory Agent and TYRO3, AXL, MER (TAM) Inhibitor
29 Dec 2017 TherapeuticsMD Announces Submission of New Drug Application for TX-001HR
28 Dec 2017 Odonate Therapeutics Announces Initiation of CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Locally Advanced or Metastatic Breast Cancer
28 Dec 2017 Esketamine Phase 2 Data Published in JAMA Psychiatry Showed Significant Improvement of Depressive Symptoms in People with Treatment-Resistant Depression
28 Dec 2017 GW Pharmaceuticals Announces Acceptance of NDA Filing for Epidiolex® (cannabidiol) in the treatment of Lennox-Gastaut syndrome and Dravet syndrome
27 Dec 2017 CStone Files MEK Inhibitor CS3006 for Clinical Trial Approval in Australia
27 Dec 2017 Diffusion Pharmaceuticals Begins Phase 3 Clinical Trial with TSC in Glioblastoma Multiforme

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top